Zoetis (NYSE:ZTS) Stock Sale Disclosed by Sen. Shelley Moore Capito

Senator Shelley Moore Capito (Republican-West Virginia) recently sold their entire stake in Zoetis Inc. (NYSE:ZTS). In a filing disclosed on November 4th, the Senator disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on October 21st.

Senator Shelley Moore Capito also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 10/21/2026.

Zoetis Trading Down 3.2%

Shares of NYSE ZTS opened at $79.50 on Friday. Zoetis Inc. has a 12 month low of $68.77 and a 12 month high of $132.49. The company has a market cap of $32.85 billion, a price-to-earnings ratio of 13.52, a P/E/G ratio of 1.23 and a beta of 0.67. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The business has a fifty day simple moving average of $75.68 and a 200-day simple moving average of $92.60.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the prior year, the firm posted $1.70 earnings per share. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. Sell-side analysts predict that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio is 34.93%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ZTS. BlackRock Inc. raised its holdings in shares of Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. State Street Corp raised its holdings in shares of Zoetis by 1.8% during the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock worth $1,413,323,000 after purchasing an additional 343,322 shares during the last quarter. Bank of America Corp DE raised its holdings in Zoetis by 7.3% in the 1st quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock valued at $571,150,000 after acquiring an additional 327,313 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Zoetis by 5.8% during the second quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after purchasing an additional 319,709 shares in the last quarter. Finally, Swedbank AB increased its stake in shares of Zoetis by 9.9% during the 1st quarter. Swedbank AB now owns 3,004,200 shares of the company’s stock worth $355,126,000 after purchasing an additional 269,610 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on ZTS. BNP Paribas Exane reduced their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings upgraded Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 29th. Citigroup lowered their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. JPMorgan Chase & Co. reduced their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Finally, Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research note on Tuesday, August 25th. Eight investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $101.25.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
• Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
• Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results

About Senator Capito

Shelley Moore Capito (Republican Party) is a member of the U.S. Senate from West Virginia. She assumed office on January 3, 2015. Her current term ends on January 3, 2027. Capito (Republican Party) ran for re-election to the U.S. Senate to represent West Virginia. She won in the general election on November 3, 2020. Capito was first elected to the Senate in 2014, becoming the first female U.S. Senator in the state’s history. Prior to serving in the Senate, Capito was a member of the West Virginia House of Representatives from 1997 to 2001 and a member of the United States House of Representatives from 2001 to 2015. At the start of the 116th Congress, Capito was a member of the U.S. Senate committees on Appropriations, Commerce, Science, and Transportation, Environment and Public Works, and Rules and Administration. As of a 2014 analysis of multiple outside rankings, Capito is a more moderate right of center Republican Party vote. As a result, she may break with the Republican Party line more than her fellow members. Capito earned her bachelor’s degree from Duke University. After earning her M.Ed. from the University of Virginia, Capito was a college counselor and then director of an educational information center. She was the only Republican in the West Virginia congressional delegation until the 2010 elections and is the first Republican woman elected to Congress from West Virginia. Capito is a former chairwoman of the Congressional Caucus for Women’s Issues, as well as a member of the Congressional Arts Caucus. After an explosion responsible for the death of 29 coal workers, Capito founded the Congressional Coal Caucus. Prior to her election to the U.S. House, Capito served in the West Virginia House of Delegates.

Zoetis Company Profile

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013.